Mankind Pharma, one of the best-leading pharmaceutical companies in India, is now accessing BSV Group, which is a biotech company previously recognized as Bharat Serum and Vaccines (PE Advent International) for an estimated value of Rs 13,630 crore.
The business deal marked a significant leap for Mankind Pharmacy, positioning it as a market leader in India’s women's health and fertility drug market, providing access to different higher-entry barrier products in critical care with the help of research and developmental technology platforms.
The business deal has significantly positioned Mankind as the number one player, with 11,000 crore and a 13% share in the gynecology market. Mankind is ranked third at present, with a 7% share of the market, whereas BSV has a 6% share.
The deal will be sponsored through internal accruals in the presence of debt and equity. BSV consisted of in-house manufacturing as well as research and development platforms. For the last few months, the deal was being prepared with the largest buyout group, EQT in Europe, with an investment done by ADIA (Abu Dhavi Investment Authority) and some other bidders.
Nowadays, BSV has undergone some developments in recombinants and in-house niche biological products, reflecting its wide research and developmental area. In the financial year 2024, the company is reported to be worth 1,723 crore, a rise of 20% in the market.
The company’s depository offers women’s health, covering the complete cycle from fertility to post-pregnancy. In November 2019, Advent often acquired a majority stake of $500 million from Bharat Serum and Vaccines.
The vice chairman of Mankind, Rajiv Juneja, said that the company believes in the women's health and fertility segments, which could work as an opportunity for stronger growth visibility in the global market. The strategic vision of the company is to expand its reach in a more competitive market.
